Chinese Authorities To Contain Number Of New Pharmaceutical Companies
This article was originally published in PharmAsia News
In a recent proposal to expedite the restructuring of China's healthcare industry, the State FDA, the Ministry of Industry and Information Technology and the Ministry of Health have requested that the country's regional FDA offices raise technology requirements during drug review and approval to curb the number of new pharmaceutical companies
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.